| scholarly article | Q13442814 |
| P50 | author | Karen E Knudsen | Q58854470 |
| Adam P. Dicker | Q37384520 | ||
| P2093 | author name string | Agnieszka K Witkiewicz | |
| Erik S Knudsen | |||
| P2860 | cites work | Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a | Q24316348 |
| Growth suppression by p16ink4 requires functional retinoblastoma protein | Q24317567 | ||
| A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 | Q24322196 | ||
| Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a | Q24324559 | ||
| Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1) | Q24685138 | ||
| Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts | Q27851556 | ||
| Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure | Q27851564 | ||
| Human papillomavirus and survival of patients with oropharyngeal cancer. | Q27851567 | ||
| CDK inhibitors: positive and negative regulators of G1-phase progression | Q27860983 | ||
| Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins | Q28201264 | ||
| Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) | Q28249012 | ||
| Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation | Q28249159 | ||
| Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers | Q28251857 | ||
| A cell cycle regulator potentially involved in genesis of many tumor types | Q28251933 | ||
| Targeting the RB-pathway in cancer therapy | Q42021453 | ||
| Paradoxical down-regulation of p16 mRNA with advancing age in acute myeloid leukemia | Q42252640 | ||
| Tumour biology: senescence in premalignant tumours | Q42802962 | ||
| Loss of Rb overrides the requirement for ERK activity for cell proliferation | Q44204100 | ||
| Mutations associated with familial melanoma impair p16INK4 function | Q52537796 | ||
| p16INK4A is a robust in vivo biomarker of cellular aging in human skin | Q53605130 | ||
| Suppressing cancer: the importance of being senescent | Q53663083 | ||
| Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 | Q59082348 | ||
| Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines | Q60200187 | ||
| Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB | Q72744200 | ||
| Expression of p16 and lack of pRB in primary small cell lung cancer | Q73147321 | ||
| Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients | Q73738326 | ||
| Cell cycle control and cancer | Q74678692 | ||
| Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer | Q77827926 | ||
| Role of the p16 tumor suppressor gene in cancer | Q28265169 | ||
| Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4 | Q28266936 | ||
| Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization | Q28290083 | ||
| A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma | Q28296086 | ||
| Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints | Q29617405 | ||
| The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product | Q29618372 | ||
| BRAFE600-associated senescence-like cell cycle arrest of human naevi | Q29619550 | ||
| Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product | Q33589833 | ||
| Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells | Q33812043 | ||
| Progression model for pancreatic cancer. | Q34012494 | ||
| Tailoring to RB: tumour suppressor status and therapeutic response | Q34040108 | ||
| Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial | Q34193953 | ||
| Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically | Q34248718 | ||
| Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. | Q34295864 | ||
| Retinoblastoma protein partners | Q34305195 | ||
| Retinoblastoma tumor suppressor: where cancer meets the cell cycle | Q34543916 | ||
| Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial | Q34749494 | ||
| Oncogenic Braf induces melanocyte senescence and melanoma in mice | Q34974162 | ||
| The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer | Q35191588 | ||
| Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression | Q35206804 | ||
| Regulation of CYL/cyclin D genes by colony-stimulating factor 1 | Q35657723 | ||
| Dual Mechanisms for the Inhibition of E2F Binding to RB by Cyclin-Dependent Kinase-Mediated RB Phosphorylation | Q36573000 | ||
| Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors | Q36707456 | ||
| E2F-associated chromatin modifiers and cell cycle control | Q37006854 | ||
| The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas | Q37038629 | ||
| Cellular mechanisms of tumour suppression by the retinoblastoma gene. | Q37225340 | ||
| The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. | Q37402233 | ||
| Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. | Q37421677 | ||
| Human papillomavirus and head and neck cancer | Q37571356 | ||
| The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression | Q39628604 | ||
| S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53. | Q39668378 | ||
| Role of the CDKN2A locus in patients with multiple primary melanomas | Q39715038 | ||
| Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis | Q40213166 | ||
| Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. | Q40492303 | ||
| P433 | issue | 15 | |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 2497-2503 | |
| P577 | publication date | 2011-08-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Cell Cycle | Q1254166 |
| P1476 | title | The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments | |
| P478 | volume | 10 |
| Q36154459 | A Network of Genes Antagonistic to the LIN-35 Retinoblastoma Protein ofCaenorhabditis elegans |
| Q38814312 | A diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment |
| Q37645370 | A genotoxic stress-responsive miRNA, miR-574-3p, delays cell growth by suppressing the enhancer of rudimentary homolog gene in vitro |
| Q64230842 | Absence of human papillomavirus in oral cavity squamous cell carcinomas among Saudi patients |
| Q59133878 | Ageing, Cellular Senescence and Neurodegenerative Disease |
| Q57116328 | Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation |
| Q56337548 | Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study |
| Q37998530 | Biomarkers for cervical cancer screening: the role of p16INK4ato highlight transforming HPV infections |
| Q41667438 | Bowen's disease with features resembling myrmecia wart |
| Q24323184 | Breast cancer-derived K172N, D301V mutations abolish Na+/H+ exchanger regulatory factor 1 inhibition of platelet-derived growth factor receptor signaling |
| Q41198328 | CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib |
| Q42704187 | CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models |
| Q34227791 | CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer |
| Q37420058 | CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion |
| Q38616175 | CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation |
| Q49544319 | Cell Cycle Regulation in Treatment of Breast Cancer. |
| Q92592825 | Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy |
| Q91272444 | Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer |
| Q47319160 | Ciliated muconodular papillary tumor of the lung harboring BRAF V600E mutation and p16INK4a overexpression without proliferative activity may represent an example of oncogene-induced senescence |
| Q52685122 | Clinical analysis of adult Philadelphia chromosome-positive acute lymphoblastic leukemia with p16 gene deletion |
| Q38533617 | Clinicopathological and immunohistological features of polypoid endometriosis |
| Q55109242 | Clinicopathological significance of p16, cyclin D1, Rb and MIB-1 levels in skull base chordoma and chondrosarcoma. |
| Q39223192 | CtBP2 contributes to malignant development of human esophageal squamous cell carcinoma by regulation of p16INK4A |
| Q61810745 | Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate |
| Q53138436 | Detecting DNA Methylation of the BCL2 , CDKN2A and NID2 Genes in Urine Using a Nested Methylation Specific Polymerase Chain Reaction Assay to Predict Bladder Cancer |
| Q50033722 | Detection of HPV16 in Esophageal Cancer in a High-Incidence Region of Malawi |
| Q42209123 | Detection of human papillomavirus (HPV) in patients with squamous cell carcinoma and the clinical characteristics of HPV-positive cases. |
| Q34103945 | Differential gene expression profile of first-generation and second-generation rapamycin-resistant allogeneic T cells |
| Q91723050 | Double amplifications of CDK4 and MDM2 in a gastric inflammatory myofibroblastic tumor mimicking cancer with local invasion of the spleen and diaphragm |
| Q33846805 | Downregulation of P16 promotes cigarette smoke extract-induced vascular smooth muscle cell proliferation via preventing G1/S phase transition |
| Q38726540 | Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells |
| Q37652328 | Effect of tumor suppressor gene cyclin-dependent kinase inhibitor 2A wild-type and A148T mutant on the cell cycle of human ovarian cancer cells |
| Q100166478 | Evasion of Oncogene Induced Senescence Due to p16INK4A Defects |
| Q100166487 | Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects |
| Q35758932 | Expression Analysis of Genes Involved in the RB/E2F Pathway in Astrocytic Tumors |
| Q35863172 | Expression of p16 in squamous cell carcinoma of the mobile tongue is independent of HPV infection despite presence of the HPV-receptor syndecan-1 |
| Q41949825 | Expression of p16 protein in infantile hemangioma |
| Q41468886 | Folding of a cyclin box: linking multitarget binding to marginal stability, oligomerization, and aggregation of the retinoblastoma tumor suppressor AB pocket domain |
| Q38536371 | Forging a signature of in vivo senescence |
| Q37230991 | Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine |
| Q36725425 | HNdb: an integrated database of gene and protein information on head and neck squamous cell carcinoma. |
| Q37481203 | Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma. |
| Q36961667 | Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation |
| Q91643878 | Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma |
| Q47550062 | Identification of Head and Neck Cancer Subtypes Based on Human Papillomavirus Presence and E2F-Regulated Gene Expression |
| Q54123926 | Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas. |
| Q33913936 | Increased risk of brain metastases in women with breast cancer and p16 expression in metastatic lymph-nodes |
| Q97075198 | Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma |
| Q96172104 | Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies |
| Q35757333 | Involvement of PSMD10, CDK4, and Tumor Suppressors in Development of Intrahepatic Cholangiocarcinoma of Syrian Golden Hamsters Induced by Clonorchis sinensis and N-Nitrosodimethylamine. |
| Q64950560 | Mapping of human papilloma virus, p16, and epstein-barr virus in non-malignant tonsillar disease. |
| Q36590413 | Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities |
| Q37225495 | Mitochondrial ribosomal protein S18-2 is highly expressed in endometrial cancers along with free E2F1. |
| Q41021890 | Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets |
| Q38264616 | Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art |
| Q93384341 | Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review |
| Q35574209 | Novel p16 binding peptide development for p16-overexpressing cancer cell detection using phage display |
| Q51295478 | Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct |
| Q90364568 | P16 as a marker of carcinoma in effusions and peritoneal washing |
| Q98463455 | PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance |
| Q91522518 | Pan-cancer molecular analysis of the RB tumor suppressor pathway |
| Q42149012 | Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells |
| Q40637500 | Prevalence of human papillomavirus in oral squamous cell carcinomas in northern Spain. |
| Q42132289 | Prognostic impact of p16 and p21 on gastroenteropancreatic neuroendocrine tumors |
| Q35620241 | RB-Pathway Disruption Is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer |
| Q33602076 | Recent advances of highly selective CDK4/6 inhibitors in breast cancer |
| Q35152839 | Relationships among folate, alcohol consumption, gene variants in one-carbon metabolism and p16INK4a methylation and expression in healthy breast tissues. |
| Q44568047 | Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma. |
| Q27022834 | Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions |
| Q34936658 | Role of DNA Methylation in Cell Cycle Arrest Induced by Cr (VI) in Two Cell Lines |
| Q45152094 | Secondary malignancies of the uterine cervix: a potential diagnostic pitfall |
| Q36140625 | Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer |
| Q28088672 | Senescence from G2 arrest, revisited |
| Q38104238 | Signaling through cyclin D-dependent kinases |
| Q90700659 | Stabilization of Cyclin-Dependent Kinase 4 by Methionyl-tRNA Synthetase in p16INK4a-Negative Cancer |
| Q36103306 | Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma |
| Q39048659 | Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth |
| Q64094681 | Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation |
| Q49547342 | Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer |
| Q40197071 | Techniques to Induce and Quantify Cellular Senescence |
| Q92874803 | The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2- Metastatic Breast Cancer: Biological Mechanisms and New Treatments |
| Q39183079 | The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies |
| Q37368732 | The cyclin-dependent kinase inhibitor p16INK4a physically interacts with transcription factor Sp1 and cyclin-dependent kinase 4 to transactivate microRNA-141 and microRNA-146b-5p spontaneously and in response to ultraviolet light-induced DNA damage |
| Q92797390 | The effects of cigarette smoking extracts on cell cycle and tumor spread: novel evidence |
| Q34460347 | The history and future of targeting cyclin-dependent kinases in cancer therapy |
| Q34038585 | The molecular balancing act of p16(INK4a) in cancer and aging |
| Q36903218 | The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer |
| Q38927182 | The protective effect of p16(INK4a) in oral cavity carcinomas: p16(Ink4A) dampens tumor invasion-integrated analysis of expression and kinomics pathways. |
| Q38208520 | The role of epigenetics in the biology of multiple myeloma. |
| Q36130090 | Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. |
| Q48227806 | Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion |
| Q28289181 | Tumour selective targeting of cell cycle kinases for cancer treatment |
| Q91828723 | Upregulated LINC00565 Accelerates Ovarian Cancer Progression By Targeting GAS6 |
| Q86887079 | p16 INK4a overexpression and p16/Ki-67 dual labeling versus conventional urinary cytology in the evaluation of urothelial carcinoma |
| Q36921242 | p16(INK4A) represses the paracrine tumor-promoting effects of breast stromal fibroblasts. |
| Q34988794 | p16(INK4a) expression in retinoblastoma: a marker of differentiation grade |
| Q36520748 | p16INK4A represses breast stromal fibroblasts migration/invasion and their VEGF-A-dependent promotion of angiogenesis through Akt inhibition. |
| Q41970277 | α-Fucosidase as a novel convenient biomarker for cellular senescence |
Search more.